| Brian A Grus, MD | |
|
20 Progress Point Pkwy Ste 108, O Fallon, MO 63368-2207 | |
| (636) 344-2400 | |
| Not Available |
| Full Name | Brian A Grus |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 32 Years |
| Location | 20 Progress Point Pkwy Ste 108, O Fallon, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053421065 | NPI | - | NPPES |
| 205144702 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 101019 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bjc Home Care Services | Saint louis, MO | Home health agency |
| Med-staff Home Health, Llc | Saint louis, MO | Home health agency |
| Kindred At Home | Creve coeur, MO | Home health agency |
| Aw Health Care | Saint louis, MO | Home health agency |
| Missouri Baptist Medical Center | Town and country, MO | Hospital |
| Progress West Hospital | O fallon, MO | Hospital |
| Barnes-jewish St Peters Hospital | Saint peters, MO | Hospital |
| St Lukes Hospital | Chesterfield, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ssm Select Rehab St Louis Llc | 2567510449 | 130 |
| Physician Groups Lc | 3072421254 | 409 |
News Archive
arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it has entered into a long-term strategic alliance with Shire Pharmaceuticals.
This study simply confirms these reassuring points: that consumers have minute exposures to BPA and DEHP from food sources, and that the substances do not stay in the body, but are quickly eliminated through natural means.
BELLUS Health Inc. reported today its financial results for the first quarter ended March 31, 2010.
An international scientific team has developed a new small molecule -VH298- which can provoke a hypoxic response controlled from outside the cells, according to a study recently published in the magazine Nature Communications with its first authors being the expert Carles Galdeano, Beatriu de Pinós researcher at the Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry of the Faculty of Pharmacy and Food Sciences and the Institute of Biomedicine of the University of Barcelona, and Julianty Frost, from the University of Dundee.
Researchers at New York University Oral Cancer Center were awarded a $2.5 million grant (R01CA228525) from the National Cancer Institute, part of the National Institutes of Health, to study the role of artemin in oral cancer pain and growth.
› Verified 2 days ago
| Entity Name | Physician Groups Lc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285664268 PECOS PAC ID: 3072421254 Enrollment ID: O20040220001157 |
News Archive
arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it has entered into a long-term strategic alliance with Shire Pharmaceuticals.
This study simply confirms these reassuring points: that consumers have minute exposures to BPA and DEHP from food sources, and that the substances do not stay in the body, but are quickly eliminated through natural means.
BELLUS Health Inc. reported today its financial results for the first quarter ended March 31, 2010.
An international scientific team has developed a new small molecule -VH298- which can provoke a hypoxic response controlled from outside the cells, according to a study recently published in the magazine Nature Communications with its first authors being the expert Carles Galdeano, Beatriu de Pinós researcher at the Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry of the Faculty of Pharmacy and Food Sciences and the Institute of Biomedicine of the University of Barcelona, and Julianty Frost, from the University of Dundee.
Researchers at New York University Oral Cancer Center were awarded a $2.5 million grant (R01CA228525) from the National Cancer Institute, part of the National Institutes of Health, to study the role of artemin in oral cancer pain and growth.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brian A Grus, MD 20 Progress Point Pkwy Ste 108, O Fallon, MO 63368-2207 Ph: (636) 344-2400 | Brian A Grus, MD 20 Progress Point Pkwy Ste 108, O Fallon, MO 63368-2207 Ph: (636) 344-2400 |
News Archive
arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it has entered into a long-term strategic alliance with Shire Pharmaceuticals.
This study simply confirms these reassuring points: that consumers have minute exposures to BPA and DEHP from food sources, and that the substances do not stay in the body, but are quickly eliminated through natural means.
BELLUS Health Inc. reported today its financial results for the first quarter ended March 31, 2010.
An international scientific team has developed a new small molecule -VH298- which can provoke a hypoxic response controlled from outside the cells, according to a study recently published in the magazine Nature Communications with its first authors being the expert Carles Galdeano, Beatriu de Pinós researcher at the Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry of the Faculty of Pharmacy and Food Sciences and the Institute of Biomedicine of the University of Barcelona, and Julianty Frost, from the University of Dundee.
Researchers at New York University Oral Cancer Center were awarded a $2.5 million grant (R01CA228525) from the National Cancer Institute, part of the National Institutes of Health, to study the role of artemin in oral cancer pain and growth.
› Verified 2 days ago
Alexander Marinov Markov, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 20 Progress Point Pkwy Ste 200, O Fallon, MO 63368 Phone: 636-916-9615 | |
Nadia Zia, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2 Progress Point Ct, O Fallon, MO 63368 Phone: 314-317-0600 Fax: 314-317-0606 | |
Dr. Amy Kathleen Davis, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1008 Rock Creek Elementary School Dr, O Fallon, MO 63366 Phone: 636-281-4410 Fax: 636-281-4412 | |
Dr. Saadia Taufiq Raza, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 6704 Keaton Corp Pkwy, O Fallon, MO 63368 Phone: 636-300-9596 Fax: 636-300-9598 | |
Dr. Genevieve Catherine Matthews, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 20 Progress Point Pkwy Ste 108, O Fallon, MO 63368 Phone: 636-344-2400 Fax: 636-344-2401 | |
Neal Holzum, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2 Progress Point Ct, Ste 101a, O Fallon, MO 63368 Phone: 636-236-9945 |